Search clinical trials for: GSK598809

Total 12 results

GlaxoSmithKline

Completed

Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement

Substance Dependence

United Kingdom
GlaxoSmithKline

Completed

A Healthy Volunteer Study to Investigate the Relative Bioavailability of Two Forms of GSK598809 Capsules.

Substance Dependence

United Kingdom
GlaxoSmithKline

Completed

A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809

Substance Dependence

Germany
GlaxoSmithKline

Completed

A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers

Substance Dependence

Germany
Massachusetts General Hospital
National Institute on Drug Abuse (NIDA); GlaxoSmithKline; Mclean Hospital

Completed

Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse Prevention

Nicotine Dependence

United States
GlaxoSmithKline

Completed

A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward

Substance Dependence

United States
GlaxoSmithKline

Completed

Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males.

Healthy Subjects

Canada
GlaxoSmithKline

Withdrawn

Effects of GSK598809 on Brain Activation in Abstinent Alcoholics

Alcohol Dependence | Substance Dependence
GlaxoSmithKline

Completed

Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809

Substance Dependence

United Kingdom
GlaxoSmithKline

Completed

EtOH Interaction Study

Substance Dependence

Netherlands
GlaxoSmithKline

Withdrawn

Relapse Prevention Study in Newly Abstinent Smokers

Substance Dependence

United States
Medical University of Graz

Completed

Pilot Study of Physostigmine-Enhanced Opioid Analgesia (PHANOS)

Postoperative Pain

Austria

3

Subscribe